Work

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Year: 2019

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-19-b109

Authors: Filip Janku, Faye M. Johnson, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Martin Forester, Sarah P. Blagden, Andreas Wicki, Debora Schmitz, Alex A. Adjei

Institutions: The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, Case Comprehensive Cancer Center, Vall d'Hebron Institute of Oncology, University College London, University of Oxford, University Hospital of Basel, PIQUR Therapeutics (Switzerland), Mayo Clinic

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2993466570

Cites:

Cited by: 7

Related to: 10